United States
Arstat Pharmaceuticals is revolutionizing women's health with a portfolio of four drug candidates, protected by 12 U.S. patents and a European (EPO) patent. Two products are Phase III-ready (confirmed by the FDA), and two are ready for Phase IIb, targeting an addressable U.S. market of approximately 50 million women, with potential peak U.S. gross sales exceeding $3.4 billion.
One of the standout assets is Nuvocept – the first oral contraceptive explicitly designed for women with overweight and obesity. Endorsed by the FDA, Nuvocept is expected to dominate a multi-billion-dollar segment of the US contraceptive market, addressing a high public health priority.
The company is led by Arkady Rubin, Ph.D., a seasoned industry expert with over 30 years of experience, including at J&J and Pfizer, renowned as a co-inventor of Ortho Tri-Cyclen Lo, the top-selling U.S. oral contraceptive.
In addition to the existing pipeline, Arstat is engaged in proprietary R&D, with potential game-changers in women's health such as PREMRING for uterine fibroids and endometriosis and ENHANTA, a non-hormonal therapy for painful and heavy menstrual periods.
Founded in 2021 and headquartered in the United States, ARSTAT Pharmaceuticals is poised to make significant strides in transforming women's health with its innovative product portfolio.
For further details, visit the company's website at www.arstatinfo.com.
